No. |
Drug (Description in trials) |
DrugBank |
KEGG DRUG * |
KEGG GENES * [Number of genes] |
KEGG PATHWAY [Number of pathways] |
Disease ID * [Number of diseases] |
1 |
Acetylcysteine |
Acetylcysteine |
D00221 |
- |
- |
[14] 6, 13, 19, 20, 49, 51, 58, 85, 94, 111, 164, 233, 298, 299 |
2 |
Dantrolene |
Dantrolene |
D02274, D02347 |
- |
- |
[1] 233 |
3 |
Dantrolene sodium |
Dantrolene |
D02274, D02347 |
- |
- |
[1] 233 |
4 |
Deferiprone |
Deferiprone |
D07416 |
- |
- |
[5] 2, 6, 120, 122, 233 |
5 |
Exenatide |
Exenatide |
D04121 |
[1] GLP1R |
[3] Insulin secretion, Neuroactive ligand-receptor interaction, cAMP signaling pathway |
[3] 6, 193, 233 |
6 |
Metformin |
Metformin |
D00944, D04966 |
[2] PRKAA1, PRKAA2 |
[19] AMPK signaling pathway, Adipocytokine signaling pathway, Apelin signaling pathway, Autophagy - animal, Circadian rhythm, Fluid shear stress and atherosclerosis, FoxO signaling pathway, Glucagon signaling pathway, Hypertrophic cardiomyopathy (HCM), Insulin resistance, Insulin signaling pathway, Longevity regulating pathway, Longevity regulating pathway - multiple species, Non-alcoholic fatty liver disease (NAFLD), Oxytocin signaling pathway, PI3K-Akt signaling pathway, Thermogenesis, Tight junction, mTOR signaling pathway |
[16] 6, 13, 46, 49, 67, 75, 77, 81, 86, 113, 158, 206, 225, 233, 265, 285 |
7 |
Sitagliptin |
Sitagliptin |
D08516 |
[1] DPP4 |
[1] Protein digestion and absorption |
[3] 75, 233, 299 |
8 |
Sitagliptin and metformin |
Sitagliptin |
D08516 |
[1] DPP4 |
[1] Protein digestion and absorption |
[1] 233 |
9 |
Sodium valproate 200mg e/c tablet |
Valproic acid |
D00399 |
[7] ABAT, ALDH5A1, CACNA1G, CACNA1H, CACNA1I, GAD1, GAD2 |
[17] Alanine, aspartate and glutamate metabolism, Aldosterone synthesis and secretion, Butanoate metabolism, Calcium signaling pathway, Circadian entrainment, Cortisol synthesis and secretion, Cushing syndrome, GABAergic synapse, GnRH secretion, MAPK signaling pathway, Metabolic pathways, Propanoate metabolism, Taurine and hypotaurine metabolism, Type I diabetes mellitus, Type II diabetes mellitus, Valine, leucine and isoleucine degradation, beta-Alanine metabolism |
[1] 233 |
10 |
Valproate |
Valproic acid |
D00399 |
[7] ABAT, ALDH5A1, CACNA1G, CACNA1H, CACNA1I, GAD1, GAD2 |
[17] Alanine, aspartate and glutamate metabolism, Aldosterone synthesis and secretion, Butanoate metabolism, Calcium signaling pathway, Circadian entrainment, Cortisol synthesis and secretion, Cushing syndrome, GABAergic synapse, GnRH secretion, MAPK signaling pathway, Metabolic pathways, Propanoate metabolism, Taurine and hypotaurine metabolism, Type I diabetes mellitus, Type II diabetes mellitus, Valine, leucine and isoleucine degradation, beta-Alanine metabolism |
[6] 2, 3, 90, 102, 233, 256 |